Trastuzumab, initially for HER2+ breast cancer, targets HER2 tyrosine kinase activity critical for cell proliferation, which is present also in osteosarcoma cells, indicating its potential for osteosarcoma therapy (84, 85). Here, ERBB2 is linked to breast carcinoma.